Comparative Evaluation of AAV8 and AAV9 Gene Therapy in Fabry Knockout (Gla−/y) and Symptomatic (G3STg/+Gla−/y) Murine Models
Genes · 2025
DOI: 10.3390/genes16070766 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Fu-Pang Chang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan. Hauptthemen laut MEDLINE: Fabry Disease, Genetic Therapy, Dependovirus, alpha-Galactosidase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council.
Abstract (Originalsprache)
Background
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene, resulting in α-galactosidase A (α-Gal A) deficiency and progressive accumulation of globotriaosylceramide (Gb3). Current therapies, such as enzyme replacement and chaperone therapy, have limitations, including incomplete biodistribution and mutation-specific efficacy. Gene therapy using adeno-associated virus (AAV) vectors presents a promising alternative.
Methods
In this study, we assessed the dose-dependent effects of AAV8 and AAV9 vectors encoding human GLA in Gla knockout (Gla−/y) mice by measuring α-Gal A activity and monitoring safety. To evaluate therapeutic efficacy, symptomatic Fabry mice (G3STg/+Gla−/y) were used.
Results
AAV9-GLA produced significantly higher and more sustained enzyme activity than AAV8-GLA across plasma, liver, heart, and kidney. In symptomatic mice, AAV9-GLA achieved superior reductions in serum Gb3 and lyso-Gb3 levels, greater Gb3 clearance in heart and kidney tissues, and improved proteinuria. Anti-GLA IgG titers remained below threshold for the first four weeks and increased modestly by week eight, indicating a limited humoral immune response. No significant clinical signs or weight loss were observed in Gla−/y mice over the 3.5-month study period, supporting the favorable safety profile of AAV-mediated gene therapy.
Conclusions
These findings demonstrate that AAV9 provides enhanced biodistribution and therapeutic efficacy compared to AAV8, supporting its potential for the treatment of Fabry disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
- Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei 11227, Taiwan.
- Department of Pediatrics, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
ORCID-Profile: Yun-Ru Chen, Dau-Ming Niu
Förderung
- National Science and Technology Council
Zitieren
APA
Chang, F. P., Lee, Y. T., Liu, P. H., Chen, P. S., Chen, Y. R., & Niu, D. M. (2025). Comparative Evaluation of AAV8 and AAV9 Gene Therapy in Fabry Knockout (Gla−/y) and Symptomatic (G3STg/+Gla−/y) Murine Models. Genes. https://doi.org/10.3390/genes16070766
Vancouver
Chang FP, Lee YT, Liu PH, Chen PS, Chen YR, Niu DM. Comparative Evaluation of AAV8 and AAV9 Gene Therapy in Fabry Knockout (Gla−/y) and Symptomatic (G3STg/+Gla−/y) Murine Models. Genes. 2025. doi:10.3390/genes16070766
BibTeX
@article{Chang2025,
author = {Chang, Fu-Pang and Lee, Ya-Ting and Liu, Pao-Hsung and Chen, Pei-Sin and Chen, Yun-Ru and Niu, Dau-Ming},
title = {Comparative Evaluation of AAV8 and AAV9 Gene Therapy in Fabry Knockout (Gla−/y) and Symptomatic (G3STg/+Gla−/y) Murine Models},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16070766}
}
EUVIMED